Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors

Gynecologic Oncology

Volumn 75, Issue 1, 1999, Pages 72-77

  Yamada, S Diane ^a   Baldwin, Rae Lynn ^a   Karlan, Beth Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Growth; Matrix metalloproteinase; Ovarian cancer; Transforming growth factor ; Transforming growth factor receptor

Indexed keywords

GELATIN; GELATINASE A; MATRIX METALLOPROTEINASE; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CULTURE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIGAND BINDING; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

EID: 0032848011     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5535     Document Type: Article

References (33)

1. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;13.
2. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 67:1998;753-791.
3. Lopez-Casillas F, Wrana J L, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 73:1993;1435-1444.
4. Wrana J L, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
5. Heldin C, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
6. Hoosein N, McKnight M, Levine A, Mulder K, Childress K, Brattain D, Brattain M. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth β-1. Exp Cell Res. 181:1989;442-453.
7. Chang J, Park K, Bang Y, Kim W, Kim D, Kim S. Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 57:1997;2856-2859.
8. Grady W M, Rajput A, Myeroff L, Liu D F, Kwon K, Willis J, Markowitz S. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58:1998;3101-3104.
9. Wang J, Sun L, Myeroff L, Wang X, Gentry L, Yang J, Liang J, Zborowska E, Markowitz S, Willson J, Brattain M. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 270:1995;22044-22049.
10. Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. 58:1998;4805-4810.
11. Sehgal I, Baley P A, Thompson T C. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res. 56:1996;3359-3365.
12. Bristow R E, Baldwin R L, Yamada S D, Korc M, Karlan B Y. Altered expression of transforming growth factor β ligands and receptors in primary and recurrent ovarian carcinomas. Cancer. 85:1999;658-668.
13. Hurteau J, Rodriguez G C, Whitaker R S, Shah S, Mills G, Bast R C, Berchuck A. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 74:1994;93-99.
14. Karlan B Y, Baldwin R L, Cirisano F D, Mamula P W, Jones J, Lagasse L. Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Gynecol Oncol. 59:1995;67-74.
15. Karlan B Y, Jones J, Greenwald M, Lagasse L. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol. 173:1995;97-104.
16. Gentry L E, Webb N R, Lim G J, Brunner A M, Ranchalis J E, Twardzik D R, Lioubin M N, Marquardt H, Purchio A F. Type I transforming growth factor-beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol. 7:1987;3418-3427.
17. Carcamo J, Weis F MB, Ventura F, Wieser R, Wrana J L, Attisano L, Massague J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol. 14:1994;3810-3821.
18. Overall C M, Wrana J L, Sodek J. Independent regulation of collagenase, 72 kDa progelatinase, and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor β J Biol Chem. 264:1989;1860-1869.
19. Agarwal C, Hembree J R, Rorke E A, Eckert R L. Transforming growth factor β1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res. 54:1994;943-949.
20. Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, Saga S, Matsuyama M. Involvement of transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res. 56:1996;3366-3370.
21. Havrilesky L J, Hurteau J A, Whitaker R S, Elbendary A, Wu S, Rodriguez G C, Bast R C, Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β Cancer Res. 55:1995;944-948.
22. Morton D M, Barrack E R. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res. 55:1995;2596-2602.
23. Smith R D. The anti-proliferative effect of transforming growth factor beta 1 on a rat intestinal epithelial cell line (RIE-1) is dependent on cell population density and culture passage number. Int J Biochem. 26:1994;899-903.
24. Weis-Garcia F, Massague J. Complementation between kinase-defective and activation-defective TGF-β receptors reveals a novel form of receptor cooperativity essential for signaling. EMBO J. 15:1996;276-289.
25. Ito M, Yasui W, Kyo E, Yokozaki H, Nakayama H, Ito H, Tahara E. Growth inhibition of transforming growth factor β on human gastric carcinoma cells: receptor and postreceptor signaling. Cancer Res. 52:1992;295-300.
26. Matrisian L M. The matrix degrading metalloproteinases. BioEssays. 14:1992;455-463.
27. Moser T L, Young T N, Rodriguez G C, Pizzo S V, Bast R C, Stack M S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer. 56:1994;552-559.
28. Tamakoshi K, Kikkawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N, Tomoda Y. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer. 76:1995;2565-2571.
29. Moore D H, Allison B, Look K Y, Sutton G P, Bigsby R M. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol. 65:1997;78-82.
30. Young T N, Rodriguez G C, Rinehart A R, Bast R C, Pizzo S V, Stack M S. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol. 62:1996;89-99.
31. Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kaupilla, Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest. 69:1993;312-321.
32. Segain J, Harb J, Gregoire M, Meflah K, Menanteau J. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. Cancer Res. 56:1996;5506-5512.
33. Martorana A M, Zheng G, Crowe T C, O'Grady R L, Lyons J G. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res. 58:1998;4970-4979.